Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.22.4
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2017
USD ($)
May 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
segment
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2007
$ / shares
Oct. 31, 2020
USD ($)
$ / shares
Oct. 01, 2020
USD ($)
Jan. 01, 2020
USD ($)
Dec. 31, 2019
USD ($)
Jan. 31, 2010
right
Basis of Presentation [Line Items]                                        
Number of business segments | segment                       1                
Maturity period of cash and cash equivalents, maximum                       3 months                
Write-downs related to obsolete inventory                       $ 1,100,000 $ 0 $ 0            
Inventory       $ 13,294,000       $ 27,326,000       13,294,000 27,326,000              
Total revenues       50,382,000 $ 59,221,000 $ 50,126,000 $ 36,516,000 56,404,000 $ 59,694,000 $ 78,854,000 $ 46,592,000 196,245,000 241,544,000 163,562,000            
Credit loss adjustments on finite-lived intangible assets       (6,500,000)       (6,500,000)       (6,500,000) (6,500,000)              
Additional reserve for credit losses due to COVID-19                       300,000 500,000              
Revenue recognized                       400,000 23,300,000              
Dividend declared (USD per share) | $ / shares                             $ 2.50          
Decrease of deferred tax liabilities       (30,615,000)       (30,856,000)       (30,615,000) (30,856,000)              
Decrease (increase) in stockholder's equity       (597,485,000)       (821,159,000)       (597,485,000) (821,159,000) (709,525,000)         $ (767,232,000)  
Additional paid-in capital                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity       (147,590,000)       (372,969,000)       (147,590,000) (372,969,000) (318,358,000)         (367,326,000)  
Retain earnings                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity       (450,862,000)       (449,090,000)       (450,862,000) (449,090,000) (391,952,000)         (400,105,000)  
Cumulative Effect, Period of Adoption, Adjustment                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity               15,997,000         15,997,000           5,168,000  
Cumulative Effect, Period of Adoption, Adjustment | Additional paid-in capital                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity               51,130,000         51,130,000              
Cumulative Effect, Period of Adoption, Adjustment | Retain earnings                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity               (35,133,000)         (35,133,000)           $ 5,168,000  
Cumulative Effect, Period of Adoption, Adjusted Balance                                        
Basis of Presentation [Line Items]                                        
Increase in carrying amount of notes               (341,100,000)         (341,100,000)              
Unamortized discount               2,200,000         2,200,000              
Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment                                        
Basis of Presentation [Line Items]                                        
Increase in carrying amount of notes               (20,400,000)         (20,400,000)              
Decrease of deferred tax liabilities               4,400,000         4,400,000              
Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | Additional paid-in capital                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity               51,100,000         51,100,000              
Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | Retain earnings                                        
Basis of Presentation [Line Items]                                        
Decrease (increase) in stockholder's equity               (35,100,000)         (35,100,000)              
Contract revenue                                        
Basis of Presentation [Line Items]                                        
Total revenues                       19,223,000 28,367,000 19,807,000            
Captisol                                        
Basis of Presentation [Line Items]                                        
Inventory       5,900,000       24,600,000       5,900,000 24,600,000              
Total revenues                       $ 104,495,000 164,250,000 109,959,000            
Stock options | 2002 Stock Incentive Plan                                        
Basis of Presentation [Line Items]                                        
Award expiration period                       10 years                
Stock options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan                                        
Basis of Presentation [Line Items]                                        
Award vesting period                       6 months                
Award vesting right (as a percent)                       12.50%                
Stock options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan                                        
Basis of Presentation [Line Items]                                        
Award vesting period                       42 months                
Award vesting right (as a percent)                       2.08%                
RSUs and PSUs                                        
Basis of Presentation [Line Items]                                        
Award vesting period                       3 years                
PSUs                                        
Basis of Presentation [Line Items]                                        
Award vesting period                       3 years                
Minimum                                        
Basis of Presentation [Line Items]                                        
Property and equipment, useful life                       3 years                
Minimum | PSUs                                        
Basis of Presentation [Line Items]                                        
Award vesting right (as a percent)                       0.00%                
Maximum                                        
Basis of Presentation [Line Items]                                        
Property and equipment, useful life                       10 years                
Maximum | PSUs                                        
Basis of Presentation [Line Items]                                        
Award vesting right (as a percent)                       200.00%                
Pfenex                                        
Basis of Presentation [Line Items]                                        
Contingent consideration liability per share (USD per share) | $ / shares                               $ 2.00        
Contingent consideration liability                               $ 77,800,000 $ 77,800,000      
Metabasis Therapeutics                                        
Basis of Presentation [Line Items]                                        
Number of contingent value rights | right                                       4
Royalty Agreements                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent) 20.00%                                      
Licensing Agreements                                        
Basis of Presentation [Line Items]                                        
Finite-lived intangible assets, net       $ 10,182,000       $ 10,110,000       $ 10,182,000 $ 10,110,000              
Licensing Agreements | Accounting Standards Update 2016-13                                        
Basis of Presentation [Line Items]                                        
Credit loss adjustments on finite-lived intangible assets                                   $ (5,500,000)    
Novan | Royalty Agreements                                        
Basis of Presentation [Line Items]                                        
Additional royalties receivable under sales-based milestones   $ 20,000,000                                    
Novan | Royalty Agreements | Minimum                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent)   7.00%                                    
Novan | Royalty Agreements | Maximum                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent)   10.00%                                    
Novan | Licensing Agreements                                        
Basis of Presentation [Line Items]                                        
Upfront payment for license   $ 12,000,000                                    
Palvella | Contract revenue                                        
Basis of Presentation [Line Items]                                        
Total revenues                           3,000,000            
Palvella | Royalty Agreements                                        
Basis of Presentation [Line Items]                                        
Additional royalties receivable under sales-based milestones     $ 8,000,000                                  
Palvella | Royalty Agreements | Minimum                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent)     5.00%                                  
Palvella | Royalty Agreements | Maximum                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent)     9.80%                                  
Palvella | Licensing Agreements                                        
Basis of Presentation [Line Items]                                        
Upfront payment for license     $ 10,000,000                                  
Finite-lived intangible assets, net                           $ 0            
Aziyo | Royalty Agreements                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent) 5.00%                                      
Proceeds from royalties received $ 10,000,000                                      
Effective interest rate of forecasted cash flows (as a percent)                       19.00%                
Aziyo | Royalty Agreements | Maximum                                        
Basis of Presentation [Line Items]                                        
Additional royalties receivable under sales-based milestones $ 10,000,000                                      
CorMatrix | Royalty Agreements                                        
Basis of Presentation [Line Items]                                        
Product royalty (as a percent) 5.00%                                      
Expiration period of royalty agreement 10 years                                      
Selexis | Royalty Agreements                                        
Basis of Presentation [Line Items]                                        
Effective interest rate of forecasted cash flows (as a percent)                       24.60%                
Dividend yield                                        
Basis of Presentation [Line Items]                                        
Measurement input (as a percent)       0               0